View Cart  

ANDA Filers Fret: Stability Testing Tweaks Will Delay Approvals

A A
The FDA’s plan to require more stability data for ANDAs is likely to slow approvals unless the agency flexes a little, generic-drug makers say.

To View This Article:

Login

Subscribe To Drug Industry Daily